Clinical Trials Directory

Trials / Unknown

UnknownNCT01085981

Assessing the Effects of a Topically Applied Cream to Clitoral Blood Flow

The Quantitative Analysis of Clitoral Blood Before and After a Topically Applied Vasodilating Cream Using Sonographic Doppler Flow Plethysmography

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
East Suburban Ob Gyn · Academic / Other
Sex
Female
Age
25 Years – 60 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine if blood flow to the clitoris is increased by topically applying a cream that causes increased blood flow. This will be measured with a sonogram.

Detailed description

On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. The patient will then be placed in an exam room and the same nurse practitioner will apply the GRAS cream or the placebo to the patients' clitoral hood with minimal manipulation. Ten minutes later the sonographer will repeat the two scans and record the same measurements as before. The patient will then come back another day to repeat the above process. Patients will be coded to assure that which ever cream they received the first visit they will get the opposite the second time. The creams will be blinded to the nurse practitioner, the patient, the sonographer, and the principle investigator. GRAS cream is arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%,

Conditions

Interventions

TypeNameDescription
DRUGarginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. With both GRAS cream and placebo.
DRUGTopical study creamOne gram applied to clitoris by nurse then ten minutes later doppler study of clitoral blood flow
DRUGGRAS cream1 gram of active cream will be applied by nurse then 10 minutes later clitoral blood flow will be assessed by doppler studies see protocol

Timeline

Start date
2010-04-01
Primary completion
2010-06-01
Completion
2010-07-01
First posted
2010-03-12
Last updated
2010-03-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01085981. Inclusion in this directory is not an endorsement.